Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

Oncogene volume 30, pages 2581–2586 (2011)Cite this article

Subjects

Abstract

Heat shock protein 90 (Hsp90) is an emerging target for cancer therapy due to its important role in maintaining the activity and stability of key oncogenic signaling proteins. We show here that the echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion protein, presumed to be the oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC), is associated with Hsp90 in cells and is rapidly degraded upon exposure of cells to IPI-504. We find EML4–ALK to be more sensitive to Hsp90 inhibition than either HER2 or mutant epidermal growth factor receptor (EGFR) with an inhibitory concentration (IC)50 for protein degradation in the low nanomolar range. This degradation leads to a potent inhibition of downstream signaling pathways and to the induction of growth arrest and apoptosis in cells carrying the EML4–ALK fusion. To generate a causative link between the expression of EML4–ALK and sensitivity to IPI-504, we introduced an EML4–ALK cDNA into HEK293 cells and show that the expression of the fusion protein sensitizes cells to IPI-504 both in vitro and in vivo. In a xenograft model of a human NSCLC cell line containing the ALK rearrangement, we observe tumor regression at clinically relevant doses of IPI-504. Finally, cells that have been selected for resistance to ALK kinase inhibitors retain their sensitivity to IPI-504. We have recently observed partial responses to administration of IPI-504 as a single agent in a phase 2 clinical trial in patients with NSCLC, specifically in patients that carry an ALK rearrangement. This study provides a molecular explanation for these clinical observations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • An WG, Schulte TW, Neckers LM . (2000). The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11: 355–360.

    CAS  PubMed  Google Scholar 

  • Bauer S, Yu LK, Demetri GD, Fletcher JA . (2006). Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66: 9153–9161.

    Article  CAS  PubMed  Google Scholar 

  • Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S et al. (2008). Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68: 4971–4976.

    Article  CAS  PubMed  Google Scholar 

  • Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J et al. (2001). The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3: 93–96.

    Article  CAS  PubMed  Google Scholar 

  • Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P et al. (2008). Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 14: 5749–5758.

    Article  CAS  PubMed  Google Scholar 

  • Fumo G, Akin C, Metcalfe DD, Neckers L . (2004). 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103: 1078–1084.

    Article  CAS  PubMed  Google Scholar 

  • Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ et al. (2008). Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 3: e0001722.

    Article  PubMed  Google Scholar 

  • Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y et al. (2006). Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 49: 4606–4615.

    Article  CAS  PubMed  Google Scholar 

  • Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ et al. (2008). EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275–4283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D et al. (2009). Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther 8: 2131–2141.

    Article  CAS  PubMed  Google Scholar 

  • Li CF, Huang WW, Wu JM, Yu SC, Hu TH, Uen YH et al. (2008). Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res 14: 7822–7831.

    Article  CAS  PubMed  Google Scholar 

  • McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL et al. (2008). HSP90 as a marker of progression in melanoma. Ann Oncol 19: 590–594.

    Article  CAS  PubMed  Google Scholar 

  • Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R et al. (2007). Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25: 5410–5417.

    Article  CAS  PubMed  Google Scholar 

  • Munster PN, Srethapakdi M, Moasser MM, Rosen N . (2001). Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 61: 2945–2952.

    CAS  PubMed  Google Scholar 

  • Neckers L . (2007). Heat shock protein 90: the cancer chaperone. J Biosci 32: 517–530.

    Article  CAS  PubMed  Google Scholar 

  • Park J, Zhao F, Zejnullahu K, Slocum K, Normant E, Engelman J et al. (2008). IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and non-T790M gefitinib-resistant lung cancer cell lines. AACR Meet Abstr abs 2450.

  • Pearl LH, Prodromou C . (2006). Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75: 271–294.

    Article  CAS  PubMed  Google Scholar 

  • Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D et al. (2007). Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110: 678–685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL et al. (2007). High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67: 2932–2937.

    Article  CAS  PubMed  Google Scholar 

  • Sequist L, Natale R, Senzer R, Martins R, Lilenbaum R, Gray J et al. (2010a). Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28: abstract 7517.

    Article  Google Scholar 

  • Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R et al. (2010b). Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28: 4953–4960.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shimamura T, Li D, Ji H, Haringsma HJ . (2008). Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 68: 5827–5838.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shimamura T, Lowell AM, Engelman JA, Shapiro GI . (2005). Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65: 6401–6408.

    Article  CAS  PubMed  Google Scholar 

  • Shimamura T, Shapiro GI . (2008). Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol 3: S152–S159.

    Article  PubMed  PubMed Central  Google Scholar 

  • Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566.

    Article  CAS  PubMed  Google Scholar 

  • Song D, Chaerkady R, Tan AC, Garcia-Garcia E, Nalli A, Suarez-Gauthier A et al. (2008). Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 7: 3275–3284.

    Article  CAS  PubMed  Google Scholar 

  • Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L et al. (2006). Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103: 17408–17413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K et al. (2009). KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143–3149.

    Article  CAS  PubMed  Google Scholar 

  • Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347–351.

    Article  CAS  PubMed  Google Scholar 

  • Tillotson B, Slocum K, Coco J, Whitebread N, Thomas B, West KA et al. (2010). Heat shock protein 90 (Hsp90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. J Biol Chem 285: 39835–39843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Young JC, Moarefi I, Hartl FU . (2001). Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154: 267–273.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. E Normant and G Paez: These authors contributed equally to this work.

Authors and Affiliations

  1. Infinity Pharmaceuticals, Cambridge, MA, USA

    E Normant, G Paez, K A West, A R Lim, K L Slocum, C Tunkey, J McDougall, A A Wylie, K Robison, K Caliri, V J Palombella & C C Fritz

Authors
  1. E Normant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Paez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K A West
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A R Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K L Slocum
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Tunkey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J McDougall
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A A Wylie
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Robison
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Caliri
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. V J Palombella
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C C Fritz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Normant.

Ethics declarations

Competing interests

The authors are employees of Infinity Pharmaceutical.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Normant, E., Paez, G., West, K. et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30, 2581–2586 (2011). https://doi.org/10.1038/onc.2010.625

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.625

Keywords

This article is cited by

Search

Advanced search

Quick links